# Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241

> **NCT00914303** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 77 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AZD3241
- **DRUG:** Placebo Tablet

## Key facts

- **NCT ID:** NCT00914303
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2010-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00914303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00914303, "Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00914303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*